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Attacking ‘prejudice’ against generics 
could save SA billions
The use of generics in South 
Africa (SA) is growing in 
line with trends in the UK 
and the USA – but is still 
nowhere near their levels. 
Local overall healthcare spend could be 
reduced by ZAR4 billion should users take 
advantage of the newer generics on the 
market.
With SA healthcare costs off the charts 
generally for brutally argued reasons (which 
the Competitions Commission enquiry will 
recommend on within months), this kind 
of saving is a no-brainer – but will require a 
major shift in perceptions on the part of both 
doctors and their patients.
This is according to Vivian Frittelli, CEO 
of the National Association of Pharma-
ceutical Manufacturers (NAPM, which 
represents the interests of generic medicine 
manufacturers and marketers in SA and the 
mission of which is to champion greater 
access to medicine for the SA population), 
and the first SA President of the International 
Generic Pharmaceutical Alliance. He told 
Izindaba that generics were often wrongly 
perceived by both doctors and patients 
to be inferior because they were cheaper. 
Sophisticated marketing by originator drug 
companies reinforced this message.
‘I worked for an originator company 
for 20-odd years and one of our messages 
was this: if your kid had meningitis, would 
you use generics? It’s the fear factor, and 
prejudices many doctors against generics – 
which the patient obviously follows.’
Frittelli said the ZAR4 billion saving was 
based on 18% of originator drugs having 
come off patent, allowing generic drugs to 
fill the gap and therefore be available for the 
taking. However, use nowhere near matched 
this because of die-hard traditional consumer 
behaviour patterns.
A recent NAPM study comparing the 
cheapest generics v. originator drug prices 
found that the difference in price of the 200 
most prescribed medicines in the private 
sector had risen to a whopping 56.1% in 
favour of generics. Explains Frittelli: ‘In 
other words, basket for basket, you’d save 
56.1% by using generics.’ Since 2010 there 
had been a steady increase in the cost 
advantage of generics over originator drugs. 
Considering that production standards 
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and manufacturing costs for both original 
and generic medicines were similar, these 
findings were ‘highly significant’, says 
Frittelli. According to IMS Health, a global 
organisation that tracks data at sales level, 
generics account for about 65% of all items 
dispensed in SA’s private sector, yet cost 
only 40% of the ZAR22 billion expenditure 
on drugs.
Using claims data from more than 
1  million medical aid members, Mediscor, 
a pharmacy benefit management organi-
sation, puts generic use at 56%, and 
growing. Based on data gleaned from IMS 
Health, every 1% increase in the use of 
generics would save consumers around 
R270 million. ‘These savings would enable 
medical schemes to offer improved benefits 
or to curb increases in premiums to their 
members. They also provide a direct benefit 
for consumers paying for medicines out of 
pocket or through their medical scheme 
savings accounts,’ adds Frittelli.
Discovery backs NAPM 
findings
Discovery Health’s publication Medicine 
Summit Journal 2015, using data from 
medical aids administered by Discovery, 
supports the NAPM findings, reporting 
a 58.8% utilisation of generics by volume 
and 46.6% by value. The Discovery summit 
also revealed that 65% of generic medicines 
are priced at 40% below their originator 
equivalents, while at least 48% of generics are 
priced at 50% or more below their originator 
equivalents. In practical terms, for a patient 
with asthma and allergic rhinitis, compli-
cated once by a fungal infection in the throat 
due to inhaler use, the savings over a year 
could be nearly ZAR4  000 should generics 
be used. The trend in SA follows that in 
the UK, where more than two-thirds of all 
medicines dispensed by the National Health 
Service (NHS) are generics yet cost only 
around 29% of the NHS drugs bill, and 
the USA, where nearly eight out of ten 
prescriptions filled are for generics, causing 
expenditure on drugs to slow despite an 
increase in the price of prescription drugs. 
‘As life expectancy increases and the cost 
of medicines escalates, the importance of 
the generics industry is being highlighted 
as it allows more people greater access to 
healthcare. The value proposition presented 
by generics cannot be disputed,’ Frittelli said.
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Mr Vivian Frittelli, CEO of the National 
Association of Pharmaceutical Manufacturers 
and the first South African President of the 
International Generic Pharmaceutical Alliance.
‘I worked for an originator 
company for 20-odd years and one 
of our messages was this: if your 
kid had meningitis, would you use 
generics? It’s the fear factor, and 
prejudices many doctors against 
generics – which the patient 
obviously follows.’
